LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy

One of the most important steps forward in management cancer was discovery immunotherapy. It has become an essential pillar treatment paradigm patients. Unfortunately, despite various options presented with immune checkpoint inhibitors (ICIs), benefit is still limited to select patients and vast majority these gain either minimal or eventually progress, leaving unmet need for development novel therapeutic agents strategies. Lymphocyte activation gene-3 (LAG-3), receptor protein, a molecule found on surface activated T-cells. plays major role negatively regulating T-cell function thereby providing tumors escape tumor microenvironment (TME). Given its importance system, LAG-3 been considered as promising target oncology precision medicine. To date, two LAG-3-directed (eftilagimod alpha relatlimab) have approved combination programmed death-1 (PD-1) setting advanced solid tumors. In this review, we discuss structure LAG-3, mechanism action, interaction ligands. We also shed light emerging treatments targeting